Endonovo Therapeutics Stock Cash And Equivalents
| ENDV Stock | USD 0.0007 0.0001 12.50% |
Endonovo Therapeutics fundamentals help investors to digest information that contributes to Endonovo Therapeutics' financial success or failures. It also enables traders to predict the movement of Endonovo Pink Sheet. The fundamental analysis module provides a way to measure Endonovo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Endonovo Therapeutics pink sheet.
Endonovo |
Endonovo Therapeutics Company Cash And Equivalents Analysis
Endonovo Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Endonovo Therapeutics Cash And Equivalents | 59.98 K |
Most of Endonovo Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Endonovo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Endonovo Therapeutics has 59.98 K in Cash And Equivalents. This is 99.99% lower than that of the Biotechnology sector and 99.99% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 100.0% higher than that of the company.
Endonovo Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Endonovo Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Endonovo Therapeutics could also be used in its relative valuation, which is a method of valuing Endonovo Therapeutics by comparing valuation metrics of similar companies.Endonovo Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Endonovo Fundamentals
| Return On Asset | -1.1 | |||
| Operating Margin | (222.06) % | |||
| Current Valuation | 9.74 M | |||
| Shares Outstanding | 194.33 M | |||
| Shares Owned By Insiders | 24.61 % | |||
| Price To Earning | (1.04) X | |||
| Price To Sales | 202.42 X | |||
| Revenue | 73.11 K | |||
| Gross Profit | 58.12 K | |||
| EBITDA | (1.51 M) | |||
| Net Income | (3.1 M) | |||
| Cash And Equivalents | 59.98 K | |||
| Total Debt | 7.36 M | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | (986.58 K) | |||
| Earnings Per Share | (0.04) X | |||
| Beta | 0.49 | |||
| Market Capitalization | 3.4 M | |||
| Total Asset | 2.01 M | |||
| Retained Earnings | (17.63 M) | |||
| Working Capital | (8.04 M) | |||
| Current Asset | 245 K | |||
| Current Liabilities | 8.29 M | |||
| Z Score | -16.0 | |||
| Net Asset | 2.01 M |
About Endonovo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Endonovo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Endonovo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Endonovo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Endonovo Pink Sheet Analysis
When running Endonovo Therapeutics' price analysis, check to measure Endonovo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Endonovo Therapeutics is operating at the current time. Most of Endonovo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Endonovo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Endonovo Therapeutics' price. Additionally, you may evaluate how the addition of Endonovo Therapeutics to your portfolios can decrease your overall portfolio volatility.